表紙:生物製剤製造の世界市場:2018年~2022年
市場調査レポート
商品コード
694204

生物製剤製造の世界市場:2018年~2022年

Global Biologics Manufacturing Market 2018-2022

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 114 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
生物製剤製造の世界市場:2018年~2022年
出版日: 2018年08月29日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 114 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

生物製剤について

生物製剤、生物(バイオ)医薬品、生物学的薬剤は、ヒト、植物および動物のような生き物に由来する生物材料から抽出、合成、および製造される薬剤を指します。生物製剤製造は、そのような薬物の製造を指します。

Technavioのアナリストは、2018年から2022年の間に、世界の生物製剤製造市場が9.11%のCAGRで成長すると予測しています。

当レポートでは、世界の生物製剤製造市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 調査方法

第4章 市場状況

  • 市場のエコシステム
  • 市場特性
  • 市場セグメンテーション分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2017年)
  • 市場規模および予測(2017-2022年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市場状況

第7章 市場セグメンテーション:技術別

  • セグメンテーション:技術別(2017-2022年)
  • 比較:技術別
  • 内製
  • 外注
  • 市場機会:技術別

第8章 市場セグメンテーション:製品別

  • セグメンテーション:製品別(2017-2022年)
  • 比較:製品別
  • 生物製剤
  • バイオシミラー
  • 市場機会:製品別

第9章 顧客情勢

第10章 地域情勢

  • 地域別セグメンテーション(2017-2022年)
  • 地域比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 主要国
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第13章 市場動向

  • 伝統的なバイオ医薬品業界とバイオテクノロジーの新興企業との間のパートナーシップの増加
  • 生物製剤製造業のアウトソーシングの拡大
  • 新しいバイオ医薬品のFDA承認の増加

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer

第16章 付録

  • 略語のリスト
目次
Product Code: IRTNTR23716

About Biologics

Biologics, biopharmaceutical, biologic drugs, or biological drugs refer to drugs that are extracted, synthesized, and manufactured from biological material derived from living sources, such as humans, plants, and animals. Biologics manufacturing refers to the production of such drugs.

Technavio's analysts forecast the Global Biologics Manufacturing Market to grow at a CAGR of 9.11% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the biologics manufacturing market. To calculate the market size, the report considers the cost incurred for in-house manufacturing of biologics and the revenue generated by contract manufacturers of biologics across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Biologics Manufacturing Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck & Co
  • Pfizer

Market driver

  • Introduction of new biologic drugs for treating diseases
  • For a full, detailed list, view our report

Market challenge

  • High cost of branded drugs is deterring market growth
  • For a full, detailed list, view our report

Market trend

  • Rise in partnerships between traditional biopharma companies and biotechnology startups
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TECHNOLOGY

  • Segmentation by technology
  • Comparison by technology
  • In-house - Market size and forecast 2017-2022
  • Outsourced - Market size and forecast 2017-2022
  • Market opportunity by technology

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • Biologics - Market size and forecast 2017-2022
  • Biosimilars - Market size and forecast 2017-2022
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Rise in partnerships between traditional biopharma companies and biotechnology startups
  • Growing outsourcing of biologics manufacturing
  • Increase in FDA approvals for new biologics products

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Related market
  • Exhibit 02: Market characteristics
  • Exhibit 03: Market segments
  • Exhibit 04: Market definition - Inclusions and exclusions checklist
  • Exhibit 05: Market size 2017
  • Exhibit 06: Validation techniques employed for market sizing 2017
  • Exhibit 07: Global - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 08: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 09: Five forces analysis 2017
  • Exhibit 10: Five forces analysis 2022
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2017
  • Exhibit 17: Technology - Market share 2017-2022 (%)
  • Exhibit 18: Comparison by technology
  • Exhibit 19: In-house - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 20: In-house - Year-over-year growth 2018-2022 (%)
  • Exhibit 21: Outsourced - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 22: Outsourced - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: Market opportunity by technology
  • Exhibit 24: Product - Market share 2017-2022 (%)
  • Exhibit 25: Comparison by product
  • Exhibit 26: Biologics - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 27: Biologics - Year-over-year growth 2018-2022 (%)
  • Exhibit 28: Biosimilars - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 29: Biosimilars - Year-over-year growth 2018-2022 (%)
  • Exhibit 30: Market opportunity by product
  • Exhibit 31: Customer landscape
  • Exhibit 32: Global - Market share by geography 2017-2022 (%)
  • Exhibit 33: Regional comparison
  • Exhibit 34: Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 35: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 36: EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 37: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 38: APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 39: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Vendor landscape
  • Exhibit 43: Landscape disruption
  • Exhibit 44: Vendors covered
  • Exhibit 45: Vendor classification
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Amgen: Overview
  • Exhibit 48: Amgen - Business segments
  • Exhibit 49: Amgen - Organizational developments
  • Exhibit 50: Amgen - Geographic focus
  • Exhibit 51: Amgen - Key offerings
  • Exhibit 52: F. Hoffmann-La Roche: Overview
  • Exhibit 53: F. Hoffmann-La Roche- Business segments
  • Exhibit 54: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 55: F. Hoffmann-La Roche- Geographic focus
  • Exhibit 56: F. Hoffmann-La Roche- Segment focus
  • Exhibit 57: F. Hoffmann-La Roche - Key offerings
  • Exhibit 58: Johnson & Johnson: Overview
  • Exhibit 59: Johnson & Johnson- Business segments
  • Exhibit 60: Johnson & Johnson - Organizational developments
  • Exhibit 61: Johnson & Johnson - Geographic focus
  • Exhibit 62: Johnson & Johnson - Segment focus
  • Exhibit 63: Johnson & Johnson - Key offerings
  • Exhibit 64: Merck & Co.: Overview
  • Exhibit 65: Merck & Co. - Business segments
  • Exhibit 66: Merck & Co. - Organizational developments
  • Exhibit 67: Merck & Co. - Geographic focus
  • Exhibit 68: Merck & Co. - Segment focus
  • Exhibit 69: Merck & Co. - Key offerings
  • Exhibit 70: Pfizer: Overview
  • Exhibit 71: Pfizer - Business segments
  • Exhibit 72: Pfizer - Organizational developments
  • Exhibit 73: Pfizer - Geographic focus
  • Exhibit 74: Pfizer - Segment focus
  • Exhibit 75: Pfizer - Key offerings